紫杉醇联合奈达铂化疗同步放疗对食管癌近远期疗效的影响  

Effects of paclitaxel and nedaplatin combined with radiotherapy on the short-and long-term efficacy of esophageal cancer

作　　者：杨武[1] 程明[1] 于立江[2] 黄余峰 YANG Wu;CHENG Ming;YU Lijiang;HUANG Yufeng(Department of Radiotherapy,Jingjiang People’s Hospital, Jingjiang 214500, Jiangsu, China;Department of Medical Oncology, Jingjiang People’s Hospital, Jingjiang 214500, Jiangsu, China)

机构地区：[1]靖江市人民医院放疗科,江苏靖江2145000 [2]靖江市人民医院肿瘤内科,江苏靖江2145000

出　　处：《癌症进展》2019年第8期918-921,共4页Oncology Progress

摘　　要：目的研究紫杉醇联合奈达铂化疗同步放疗对食管癌近远期疗效影响。方法采用随机数字表法将82例食管癌患者随机分为对照组和观察组,每组41例。对照组患者接受单纯放射治疗,观察组患者在此基础上同步紫杉醇联合奈达铂化疗。比较两组患者的疾病控制率(DCR)、总缓解率(RR)及不良反应发生率;随访3年,比较两组患者第1、2、3年生存率和中位生存期。结果观察组患者DCR和RR分别为95.12%和70.73%,高于对照组患者的78.05%和41.46%(P<0.05)。观察组患者骨髓抑制和脱发的发生率均高于对照组患者(P<0.05)。观察组患者3年生存率高于对照组患者(P<0.05),中位生存期明显长于对照组患者(P<0.01)。结论紫杉醇联合奈达铂化疗同步放疗可提高食管癌患者的临床疗效,延长生存期,且所致不良反应均可耐受。Objective To study the effect of paclitaxel and nedaplatin combined with radiotherapy on the short- and long- term efficacy of esophageal cancer. Method A total of 82 cases of esophageal cancer were included in the study and randomized using a random number table into control group and study group, with 41 cases in each, respectively. The patients in control group accepted the radiotherapy, while the study group was additionally administered with concurrent paclitaxel and nedaplatin chemotherapy. The disease control rate (DCR), overall response rate (RR) and the incidence of adverse reactions in the two groups were compared, besides, these patients were followed up for 3 years after surgery, the survival rate and median survival time of the two groups in 1, 2, and 3 years were compared. Result The DCR and RR of the study group were 95.12% and 70.73%, which were significantly higher than those of the control group at 78.05% and 41.46%, respectively (P<0.05). The incidence of bone marrow suppression and alopecia in the study group was significantly higher than that in the control group (P<0.05). The 3-year survival rate in study group was significantly higher compared with control group (P<0.05), and so did the median survival time, showing statistically significant difference (P<0.01). Conclusion Concurrent chemoradiotherapy of paclitaxel plus nedaplatin can significantly improve the therapeutic effect of esophageal cancer, prolong the survival time, and reduce the risk of tumor metastasis, besides, the toxic and adverse effects are tolerable.

关 键 词：紫杉醇 奈达铂 同步放化疗 食管癌 不良反应 

分 类 号：R735.1[医药卫生—肿瘤]